Researchers and scientists continue to develop and test new treatments for these fatal conditions. Here’s a look at some major developments in these areas.
Some health insurers are giving members cash rewards when they choose less-expensive healthcare providers or have procedures or tests performed at lower-priced facilities.
How healthcare executives can ensure they are always in the best position to take advantage of the next career opportunity.
From EHRs that didn’t fulfill promised savings to a system that still rewards volume over value, our experts examine what’s next in the quest to cut the fat from healthcare spending.
Managed Healthcare Executive asked key opinion leaders their thoughts on the drug rebate controversy. Here’s what they said.
FDA’s new guidance provides a roadmap for health executives on incorporating EHRs into clinical trials.
A 51-year-old female patient has been taking Forteo (teriparatide) for osteoporosis for the past year. Her insurance company notifies her that the drug is no longer on its formulary.
When it comes to promising areas in the treatment of lymphoma and other blood cancers, gene therapy may be at the top of the list. Here’s why.
Artificial intelligence is about to do what we hoped to see technology do in the last decade for the health industry: Empower organizations and clinicians to improve the health, outcomes, and experience of care for more people in less time and at lower cost.
Two oncology practices have wish list items for payers. Find out what they are.